MHRA and HPRA Clear 4D Pharma’s Blautix Phase II Study
4D pharma plc announced that the Company has received clearance from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Health Products Regulatory Authority (HPRA) to commence the Phase II study of Blautix, the […]